250 9
pncA, and rpsL). We identified 67 genes with high diversity and Tajima's D values more 2 3 1 negative than expected based on gene length; only two of these were associated with 2 3 2 drug resistance (i.e. ethA and pncA). Twenty out of 51 homoplastic SNPs that are also 2 3 3 F ST outliers fall within or upstream of known drug resistance associated genes. The remaining SNPs may be false positives or novel drug resistance mutations. mutations in these and other organisms, as they are likely to be associated with 2 4 0 phenotypes such as drug resistance, heightened transmissibility, or host adaptation. However, few methods are available for identifying loci under positive selection in the 2 4 2 setting of clonal evolution. We adopted an empirical approach to this problem and used In this analysis of clinical isolates from settings with endemic drug resistance, we found 2 4 6 genome-wide diversity to be higher in susceptible M. tb sub-populations than in those 2 4 7 resistant to first-and second-line drugs (with the exception of protionamide (PRO) and susceptible populations is consistent with a significant role for transmitted resistance in transmission of resistance, rather than de novo evolution of resistance mutations during 2 5 3 infection (9). The primary studies for the sequence data analyzed here also identified 2 5 4 clusters of drug resistant isolates (5, 6) , suggesting that resistant isolates were being 2 5 5 transmitted. Our results, along with these previously published observations, suggest 2 5 6 that the fitness of drug resistant isolates can be high enough to allow them to circulate 2 5 7 in endemic regions. As discussed below, the fitness effects of M. tb drug resistance 2 5 8 mutations appear to vary substantially; the finding of transmitted resistance in this and 2 5 9 other studies suggests that the fitness of isolates harboring low-cost mutations is 2 6 0 comparable to that of susceptible M. tb. The populations in our study have a high 2 6 1 burden of drug resistant TB, and the role of transmitted drug resistance may differ in 2 6 2 other settings. An alternative -but not mutually exclusive -explanation for the observation of higher 2 6 4 diversity in susceptible populations is that drug resistant M. tb is under distinct 2 6 5 evolutionary constraints that reduce average genome-wide levels of diversity. In support 2 6 6 of this hypothesis, we identified a specific subset of genes that were invariant across 2 6 7 drug resistant populations. Interestingly, while average diversity was lower for resistant 2 6 8 sub-populations, the gene-wise diversity distributions had heavier tails, indicating there 2 6 9 were more genes with extreme levels of diversity. We found the genetic architecture of resistance to vary among targets, and resistance-2 7 2 associated genes tended to fall within categories that we term "sloppy", "tight", and 2 7 3 "hybrid" targets of selection (the latter has a combination of tight and sloppy features 2 7 4 and applies to rpsL, embB, and rpoB). "Sloppy" resistance genes are characterized by 2 7 5 high levels of diversity. Genes associated with PZA, EMB, Et, and STR resistance (i.e. pncA, gid, rpsL, rrs, ethA) have high levels of diversity; some also had an excess of rare 2 7 7 variants (pncA, ethA, embC). The finding that these genes accumulate multiple, individually rare mutations implies that there is a large target for resistance and/or 2 7 9 compensatory mutations within the gene: that is, resistance can result from multiple 2 8 0 different variants acting individually or in concert. In addition to its numerous rare segregating in a natural population suggests that alterations to these genes are 2 9 0 generally associated with negligible fitness costs. An M. tb strain harboring a deletion in 2 9 1 pncA conferring resistance to PZA was estimated to be endemic in Quebec by 1800, 2 9 2 long before the use of PZA for the treatment of TB (33) (34) (35) . This supports the idea that 2 9 3 purifying selection on pncA is relatively weak, which would contribute to its exceedingly 2 9 4 high diversity and broaden the adaptive paths to resistance. In contrast to pncA, gid, which is associated with low level STR resistance (36), does 2 9 6 not appear to have the signatures of a "sloppy" target for resistance despite its high 2 9 7 diversity. We identified just three homoplastic SNPs within gid, and previous studies 2 9 8 have found that STR resistant isolates do not encode the same gid mutations (37). This 2 9 9 could indicate that a multitude of mutations within gid confer resistance, but levels of contributed to the lack of differentiation we and others have observed between 3 0 6 putatively STR resistant and susceptible sub-populations. In addition, mutations in rpsL, 3 0 7 which cause high level resistance, could mask the contribution of gid to STR resistance. We found some drug targets to be highly diverse in resistant sub-populations of either 3 0 9 L2 or L4 (but not both), suggesting that resistance mutations in these genes interact 3 1 0 with the genetic background; the fitness effects of mutations in these genes could, for have been reported previously: for example, specific mutations in the inhA promoter have been associated with the L1 and M. africanum genetic backgrounds (40, 41) . In contrast to "sloppy" targets, we discovered individual homoplastic SNPs associated 3 1 7 with drug resistant sub-populations (i.e. with high F ST ) representing "tight" targets of 3 1 8 selection in genes conferring resistance to INH, RIF, and STR. Numerous resistance 3 1 9 mutations have been described in katG, rpoB, rpsL, embB, and gyrA, but we find drug 3 2 0 resistant sub-populations to be defined by a specific subset of mutations in these genes. This suggests that certain mutations are strongly favored relative to others conferring 3 2 2 resistance to the same drugs when M. tb is in its natural environment. Antibiotic fitness costs varying among mutations, even within the same gene (18). Mutations can 3 2 5 also have different fitness effects depending on the genetic background, but the most fit 3 2 6 mutants were the same across M. tb lineages in a study of RIF resistance (18). In our analyses, we found the dominant INH resistance mutation in katG to affect the activity (42) and is associated with lower fitness costs than other katG mutants, both in 3 3 0 vitro and in a mouse model (43, 44) . This mutation was recently shown to precede in vitro compared to other mutations conferring resistance to RIF and STR in these 3 3 5
genes (18, 44, 46) . These results suggest that many of the findings regarding the The fitness effects of mutations in gyrA (codon 94) and embB (codon 306) have not 3 3 9 been measured; based on our homoplasy and F ST results, we propose that they have 3 4 0 lower fitness costs than other mutations in these genes and that they represent "tight" 3 4 1 targets of selection. Mutations at gyrA codon 94 were previously found to be the most associated with acquisition of multiple resistances (48), and we find that this position is 3 4 5 an F ST outlier for all first line drugs in L4. This mutation is not an F ST outlier in L2 (i.e top 3 4 6 5 th percentile), with percentiles for F ST values ranging from 0.07-0.68 for first line drugs 3 4 7 in this lineage. These observations suggest that the genetic background affects 3 4 8 interactions among resistance mutations, and that embB 306 is important for acquisition 3 4 9 of multidrug resistance in L4 but not L2. We searched for indels with the signature of a "tight" target, i.e. homoplastic mutations 3 5 1 segregating at markedly different frequencies in drug susceptible and resistant sub- We identified one homoplastic indel that was also an F ST outlier -a deletion in gid that to CAP, EMB, Et, K, OFL, and PZA). Our finding that, save for the frameshift mutation in gid, indels in resistance genes do 3 6 1 not have the signature of "tight" targets suggests that they are generally associated with 3 6 2 higher fitness costs than SNPs. Fifteen drug targets have been found in transposon There are several limitations to our study. Resistance to multiple drugs was common in 3 7 0 our sample, and in some cases it was difficult to identify patterns of diversity and 3 7 1 population differentiation that were specific to individual drugs. Our results are also was heavily skewed to lineages 2 and 4, and the results are not necessarily applicable 3 7 5 to other M. tb lineages. Finally, the data analyzed here were generated with short 3 7 6 sequencing read technologies, and we were thus limited to characterizing diversity in 3 7 7 regions of the M. tb genome that can be resolved with these methods: regions that were 3 7 8 masked from analysis (e.g. due to sequence repeats) may include unknown resistance 3 7 9 targets. We also used an L4 genome (H37Rv) as a reference, and gene content specific 3 8 0 to L2 may not have been identified. We were not able to recover all drug resistance associated genes using the analyses 3 8 2 performed here. This is likely a result of limited phenotypic data for some drugs and We identified 31 SNPs that do not fall within the list of known drug resistance genes, which both emerged more than once on the phylogeny (homoplasies) and were 3 9 0 segregating at markedly different frequencies in resistant and susceptible sub- other studies (i.e. they are in genes encoding efflux pumps, genes differentially 3 9 4 regulated in resistant isolates or in response to the presence of drug, potential drug 3 9 5 targets, or genes in the same pathways as drug targets or resistance determinants) 3 9 6 (50-54). In addition to a direct, previously unrecognized role in resistance, these SNPs could compensate for fitness costs of drug resistance. For example, we identified a 3 9 8 homoplastic F ST outlier in rpoC, and mutations in rpoC have been shown to compensate 3 9 9
for RIF resistance in experimental evolution studies (22).
Intriguingly, we found lipid metabolism genes to be enriched in the list of genes 4 0 1 harboring homoplastic SNPs (p = 0.013). We've previously shown that these genes that are at markedly different frequencies in isolates with distinct lipid profiles. selection in a clonal bacterium. We found these loci to be associated with distinct 4 1 0 patterns of diversity that likely reflect differing genetic architectures underlying the traits 4 1 1 under selection. The evolutionary path to resistance is broad for some drugs with 4 1 2 "sloppy targets", whereas for drugs with "tight targets" the means of acquiring resistance 4 1 3 appear more limited. This is likely due to fitness effects of resistance mutations in M. target genes. We also found evidence suggesting that there are important interactions Efforts are underway to sequence and perform drug susceptibility testing on thousands We downloaded sequencing read data from two large surveys of drug resistant M. tb in 4 4 5 Russia (5) and South Africa (6). We used FastQC (55) and TrimGalore (56) and addition of read group information. Variants were identified using Pilon v 1.16 (59).
5 0
A detailed description of the reference guided assembly pipeline is available at 4 5 1 https://github.com/pepperell-lab/RGAPepPipe. We removed isolates with mean 4 5 2 coverage less than 20X, isolates with percentage of the genome covered at 10X less 4 5 3 than 90%, isolates where a majority of reads did not map to H37Rv, and isolates where 4 5 4 greater than 10% of sites were unknown after mapping. The final data set contains 1161 4 5 5 Table 1 Insertions and deletions were identified during variant calling with Pilon. We used Emu 4 7 0
M. tb isolates (Supplementary
(63) to normalize indels across multiple isolates. We used a presence/absence matrix 4 7 1 for the normalized indels for further analyses of indel diversity. were calculated using Egglib v 2.1.10 (64) for whole genome alignments and gene-wise 4 7 5
alignments. Isolates were further divided by lineage and drug resistance phenotype.
7 6
Sites with missing data due to indels or low quality base calls more than 5% of isolates For non-biallelic SNPs, we calculated F ST for the two most common variants. This material is based upon work supported by the National Science Foundation We thank members of the Pepperell Lab for their input on analyses and data References: 
